» Molecular subtypes that exist in paediatric and adult sarcomas. This includes a spotlight on the potential indicators that may hint at the presence of NTRK gene fusions

MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

Molecular subtypes that exist in paediatric and adult sarcomas. This includes a spotlight on the potential indicators that may hint at the presence of NTRK gene fusions

Prof. George Demetri

SARCOMA CONNECT have partnered with NTRK CONNECT to describe a number of the molecular subtypes that exist in paediatric and adult sarcomas. This includes a spotlight on the potential indicators that may hint at the presence of NTRK gene fusions.

Prof. George Demetri

Medical Oncologist

Dana Faber Cancer Institute

United States (US)

Prof. George Demetri

Medical Oncologist

Dana Faber Cancer Institute

United States (US)

Dr. George D. Demetri is Associate Professor of Medicine at Harvard Medical School and Director of the Center for Sarcoma and Bone Oncology in the Department of Medical Oncology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts. Dr. Demetri received his undergraduate degree in Biochemistry from Harvard College and medical degree from Stanford University School of Medicine in 1983, then went on to Internal Medicine residency and chief residency at the University of Washington Hospitals in Seattle. He then completed a fellowship in Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, where he has served as an Attending Physician since 1989. He is also an affiliate investigator with the Ludwig Institute for Cancer Research. Dr. Demetri’s research and clinical interests have focused on the translation of scientific discoveries into targeted drugs for the management of sarcomas as a model for solid tumor research and development. This work has led to the development of the oral drug Gleevec as an effective treatment for the gastrointestinal sarcoma known as GIST, and is continuing with the research leading to the new multi-targeted agent SU11248 for GIST resistant to Gleevec. A fellow of the American College of Physicians, Dr. Demetri is a member of many professional societies and editorial boards of scientific journals. He is a member the Board of Directors of the Connective Tissue Oncology Society and a member of the Medical Advisory Board of the Sarcoma Foundation of America. He has been instrumental in raising awareness of issues relating to drug development and sarcoma research by his activities on the Internet, and he founded a non-profit educational site for sarcoma patients and their families.

Prof. George Demetri has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

time | open 7 min | Mar 2020

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

Download PPTX

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

00:00:30
Chapter 1: From Ewing-like to Cic-Dux

00:04:12
Chapter 2: Gene fusions in paediatric and adult sarcomas

00:06:19
Chapter 3: Succinate-dehydrogenase deficient GIST

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.

Other programmes of interest

Prof Valentina Guarneri

Interactive patient case

28 min

(TEST) Oral SERDs: New Endocrine Therapy Options in ER+ Advanced ...

Sep 2023

Prof. Viktor Grünwald

Interactive patient case

11 min

Optimising treatment for advanced RCC

Jun 2023

Prof. David Hong

5 min

TRK fusion-positive cancer highlights from ASCO 2022

Jun 2022

Beth Wittmer

Prof. Hans Prenen

Podcast

20 min

Podcast: management of skin toxicity with multikinase inhibitors

Jun 2022

Prof. Chiara Cremolini

2 min

Update from ASCO 2022 - Rectal cancer & mCRC

Jun 2022

Prof. Sammy Saab

15 min

Response to immunotherapy in HCC: Real-world experience and treat...

Jun 2022

Prof. Jonathan Trent

2 min

Update from ASCO 2022 - Sarcoma

Jun 2022

Prof. Jonathan Trent

0 min

[DEMO] SARCOMA CONNECT update from ASCO 2022

May 2022

Screenshot of the video by Prof. Rebecca Dent

Dr. Rebecca Dent

Prof. Chiara Cremolini

Asst. Prof. Hans Lee

Prof. Jonathan Trent

0 min

Update From ASCO 2022 - Selected LBAs

May 2022

Brenda Martone

Assoc. Prof. Alicia Morgans

Podcast

30 min

Shared decision-making in nmCRPC: Treatment considerations to mai...

Jun 2022

Assoc. Prof. Tanya Dorff

Dr. Neal Shore

Podcast

30 min

Timing of ARSI and taxanes for mCRPC

Jun 2022

Assessing the management of hepatocellular cancer in Asia

Survey

2 min

Assessing the management of hepatocellular cancer in Asia

Jun 2022

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.